mGlu₅ negative allosteric modulators: a patent review (2013 - 2016)

References

• Niswender CM, Conn PJ. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol. 2010;50:295–322.
   PubMed Web of Science ®Google Scholar
• Lindsley CW, Emmitte KA, Hopkins CR, et al. Practical strategies and concepts in GPCR allosteric modulator discovery: recent advances with metabotropic glutamate receptors. Chem Rev. 2016;116:6707–6741.
   PubMed Web of Science ®Google Scholar
• Emmitte KA. mGlu5 negative allosteric modulators: a patent review (2010-2012). Expert Opin Ther Pat. 2013;23:393–408.
   PubMed Web of Science ®Google Scholar
• Emmitte KA. Recent advances in the design and development of novel negative allosteric modulators of mGlu(5). ACS Chem Neurosci. 2011;2:411–432.
   PubMed Web of Science ®Google Scholar
• Rocher J-P, Bonnet B, Boléa C, et al. mGluR5 negative allosteric modulators overview: a medicinal chemistry approach towards a series of novel therapeutic agents. Curr Top Med Chem. 2011;11:680–695.
   PubMed Web of Science ®Google Scholar
• Jaeschke G, Wettstein JG, Nordquist RE, et al. mGlu5 receptor antagonists and their therapeutic potential. Expert Opin Ther Pat. 2008;18:123–142.
   Web of Science ®Google Scholar
• Bach P, Isaac M, Slassi A. Metabotropic glutamate receptor 5 modulators and their potential therapeutic applications. Expert Opin Ther Pat. 2007;17:371–384.
   Web of Science ®Google Scholar
• Mihov Y, Hasler G. Negative allosteric modulators of metabotropic glutamate receptors subtype 5 in addiction: a therapeutic window. Int J Neuropsychopharmacol. 2016 ;19:1–11.
   PubMed Web of Science ®Google Scholar
• Tronci V, Vronskaya S, Montgomery N, et al. The effects of the mGluR5 receptor antagonist 6-methyl-2-(phenylethynyl)-pyridine (MPEP) on behavioural responses to nicotine. Psychopharmacology. 2010;211:33–42.
   PubMed Web of Science ®Google Scholar
• Adams CL, Short JL, Lawrence AJ. Cue-conditioned alcohol seeking in rats following abstinence: involvement of metabotropic glutamate 5 receptors. Br J Pharmacol. 2010;159:534–542.
   PubMed Web of Science ®Google Scholar
• Martin-Fardon R, Baptista MAS, Dayas CV, et al. Dissociation of the effects of MTEP [3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine] on conditioned reinstatement and reinforcement: comparison between cocaine and a conventional reinforcer. J Pharmacol Exp Ther. 2009;329:1084–1090.
   PubMed Web of Science ®Google Scholar
• Gass JT, Osborne MPH, Watson NL, et al. mGluR5 antagonism attenuates methamphetamine reinforcement and prevents reinstatement of methamphetamine-seeking behavior in rats. Neuropsychopharmacology. 2009;34:820–833.
   PubMed Web of Science ®Google Scholar
• Besheer J, Grondin JJM, Salling MC, et al. Interoceptive effects of alcohol require mGlu5 receptor activity in the nucleus accumbens. J Neurosci. 2009;29:9582–9591.
   PubMed Web of Science ®Google Scholar
• Gass JT, Olive MF. Role of protein kinase C epsilon (PKCɛ) in the reduction of ethanol reinforcement due to mGluR5 antagonism in the nucleus accumbens shell. Psychopharmacology. 2009;204:587–597.
   PubMed Web of Science ®Google Scholar
• Kumaresan V, Yuan M, Yee J, et al. Metabotropic glutamate receptor 5 (mGluR5) antagonists attenuate cocaine priming- and cue-induced reinstatement of cocaine seeking. Behav Brain Res. 2009;202:238–244.
   PubMed Web of Science ®Google Scholar
• Platt DM, Rowlett JK, Spealman RD. Attenuation of cocaine self-administration in squirrel monkeys following repeated administration of the mGluR5 antagonist MPEP: comparison with dizocilpine. Psychopharmacology. 2008;200:167–176.
   PubMed Web of Science ®Google Scholar
• Iso Y, Grajkowska E, Wroblewski JT, et al. Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic glutamate receptor subtype 5 antagonists; search for cocaine medications. J Med Chem. 2006;49:1080–1100.
   PubMed Web of Science ®Google Scholar
• Kenny PJ, Boutrel B, Gasparini F, et al. Metabotropic glutamate 5 receptor blockade may attenuate cocaine self-administration by decreasing brain reward function in rats. Psychopharmacology. 2005;179:247–254.
   PubMed Web of Science ®Google Scholar
• Lee B, Platt DM, Rowlett JK, et al. Attenuation of behavioral effects of cocaine by the metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)-pyridine in squirrel monkeys: comparison with dizocilpine. J Pharmacol Exp Ther. 2005;312:1232–1240.
   PubMed Web of Science ®Google Scholar
• Tessari M, Pilla M, Andreoli M, et al. Antagonism at metabotropic glutamate 5 receptor inhibits nicotine- and cocaine-taking behaviours and prevents nicotine-triggered relapse to nicotine-seeking. Eur J Pharmacol. 2004;499:121–133.
   PubMed Web of Science ®Google Scholar
• McGeehan AJ, Olive MF. The mGluR5 antagonist MPEP reduces the conditioned rewarding effects of cocaine but not other drugs of abuse. Synapse. 2003;47:240–242.
   PubMed Web of Science ®Google Scholar
• Lindemann L, Porter RH, Scharf SH, et al. Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression. J Pharmacol Exp Ther. 2015;353:213–233.
   PubMed Web of Science ®Google Scholar
• Jaeschke G, Kolczewski S, Spooren W, et al. Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, RO4917523), a promising novel medicine for psychiatric diseases. J Med Chem. 2015;58:1358–1371.
   PubMed Web of Science ®Google Scholar
• Felts AS, Rodriguez AL, Morrison RD, et al. Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety. Bioorg Med Chem Lett. 2013;23:5779–5785.
   PubMed Web of Science ®Google Scholar
• Carcache D, Vranesic I, Blanz J, et al. Benzimidazoles as potent and orally active mGlu5 receptor antagonists with an improved PK profile. ACS Med Chem Lett. 2010;2:58–62.
   PubMed Web of Science ®Google Scholar
• Busse CS, Brodkin J, Tattersall D, et al. The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine (MTEP) in rodent models of anxiety. Neuropsychopharmacology. 2004;29:1971–1979.
   PubMed Web of Science ®Google Scholar
• Klodzinska A, Tatarczyńska E, Chojnacka-Wójcik E, et al. Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABAA signaling. Neuropharmacology. 2004;47:342–350.
   PubMed Web of Science ®Google Scholar
• Spooren WPJM, Vassout A, Neijt HC, et al. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther. 2000;295:1267–1275.
   PubMed Web of Science ®Google Scholar
• Pop AS, Gomez-Mancilla B, Neri G, et al. Fragile X syndrome: a preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development. Psychopharmacol (Berl). 2014;231:1217–1226.
   PubMed Web of Science ®Google Scholar
• Thomas AM, Bui N, Perkins JR, et al. Group I metabotropic glutamate receptor antagonists alter select behaviors in a mouse model for fragile X syndrome. Psychopharmacol (Berl). 2012;219:47–58.
   PubMed Web of Science ®Google Scholar
• Michalon A, Sidorov M, Ballard TM, et al. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron. 2012;74:49–56.
   PubMed Web of Science ®Google Scholar
• Levenga J, Hayashi S, De Vrij FM, et al. AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome. Neurobiol Dis. 2011;42:311–317.
   PubMed Web of Science ®Google Scholar
• de Vrij FMS, Levenga J, Van der Linde HC, et al. Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis. 2008;31:127–132.
   PubMed Web of Science ®Google Scholar
• Yan QJ, Rammal M, Tranfaglia M, et al. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology. 2005;49:1053–1066.
   PubMed Web of Science ®Google Scholar
• Picconi B, Calabresi P. Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson’s disease? Mov Disord. 2014;29:715–719.
   PubMed Web of Science ®Google Scholar
• Rascol O, Fox S, Gasparini F, et al. Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. Parkinsonism Relat Disord. 2014;20:947–956.
   PubMed Web of Science ®Google Scholar
• Zhang L, Balan G, Barreiro G, et al. Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator. J Med Chem. 2014;57:861–877.
   PubMed Web of Science ®Google Scholar
• Grégoire L, Morin N, Ouattara B, et al. The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys. Parkinsonian Rel Disord. 2011;17:270–276.
   PubMed Web of Science ®Google Scholar
• Rylander D, Iderberg H, Li Q, et al. A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol Dis. 2010;39:352–361.
   PubMed Web of Science ®Google Scholar
• Morin N, Grégoire L, Gomez-Mancilla B, et al. Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology. 2010;58:981–986.
   PubMed Web of Science ®Google Scholar
• Breysse N, Baunez C, Spooren W, et al. Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J Neurosci. 2002;22:5669–5678.
   PubMed Web of Science ®Google Scholar
• Overk CR, Cartier A, Shaked G, et al. Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5 – implications for dementia with Lewy bodies. Mol Neurodegener. 2014;9:18.
   PubMed Web of Science ®Google Scholar
• Hamilton A, Esseltine JL, DeVries RA, et al. Metabotropic glutamate receptor 5 knockout reduces cognitive impairment and pathogenesis in a mouse model of Alzheimer’s disease. Mol Brain. 2014;7:40.
   PubMed Web of Science ®Google Scholar
• Um JW, Kaufman AC, Kostylev M, et al. Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer Aβ oligomer bound to cellular prion protein. Neuron. 2013;79:887–902.
   PubMed Web of Science ®Google Scholar
• Chung W, Choi SY, Lee E, et al. Social deficits in IRSp53 mutant mice improved by NMDAR and mGluR5 suppression. Nat Neurosci. 2015;18:435–443.
   PubMed Web of Science ®Google Scholar
• Silverman JL, Smith DG, Rizzo SJ, et al. Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism. Sci Transl Med. 2012;4:131ra51.
   PubMed Web of Science ®Google Scholar
• Silverman JL, Tolu SS, Barkan CL, et al. Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP. Neuropsychopharmacology. 2010;35:976–989.
   PubMed Web of Science ®Google Scholar
• Hughes ZA, Neal SJ, Smith DL, et al. Negative allosteric modulation of metabolic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression. Neuropharmacology. 2013;66:202–214.
   PubMed Web of Science ®Google Scholar
• Tatarczyńska E, Kłodzińska A, Chojnacka-Wójcik E, et al. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol. 2001;132:1423–1430.
   PubMed Web of Science ®Google Scholar
• Dipraglurant structure disclosed in International nonproprietary names for pharmaceutical substances (INN). WHO Drug Inf. 2009;23:271–367.
   Google Scholar
• Vranesic I, Ofner S, Flor PJ, et al. AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization. Bioorg Med Chem. 2014;22:5790–5803.
   PubMed Web of Science ®Google Scholar
• Gasparini F, Lingenhöhl K, Stoehr N, et al. Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systematically active mGlu5 receptor antagonist. Neuropharmacology. 1999;38:1493–1503.
   PubMed Web of Science ®Google Scholar
• Cosford ND, Tehrani L, Roppe J, et al. 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J Med Chem. 2003;46:204–206.
   PubMed Web of Science ®Google Scholar
• Walles M, Wolf T, Jin Y, et al. Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects. Drug Metab Dispos. 2013;41:1626–1641.
   PubMed Web of Science ®Google Scholar
• Guerini E, Schadt S, Greig G, et al. A double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]-basimglurant and absolute bioavailability after oral administration and concomitant intravenous microdose administration of [13C6]-labeled basimglurant in humans. Xenobiotica. 2016. [Epub ahead of print]. DOI:10.3109/00498254.2016.1169334
   Web of Science ®Google Scholar
• Jacquemont S, Curie A, Des Portes V, et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med. 2011;3:64ra1.
   PubMed Web of Science ®Google Scholar
• Berry-Kravis E, Des Portes V, Hagerman R, et al. Mavoglurant in fragile X syndrome: results of two randomized, double-blind, placebo-controlled trials. Sci Transl Med. 2016;8:321ra5.
   PubMed Web of Science ®Google Scholar
• Bailey DB Jr, Berry-Kravis E, Wheeler A, et al. Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study. J Neurodev Disord. 2016;8:1. DOI:10.1186/s11689-015-9134-5
   PubMed Web of Science ®Google Scholar
• Quiroz J, Wasef E, Wong CY, et al. Effect of two doses of basimglurant on behavioral symptoms in adolescent and adult patients with Fragile X Syndrome; results from Fragxis, a double-blind, placebo controlled study. Presented at 2015 International Meeting for Autism Research; 2015 May 15; Salt Lake City, UT.
   Google Scholar
• Mullard A. Fragile X disappointments upset autism ambitions. Nat Rev Drug Discov. 2015;14:151–153.
   PubMed Web of Science ®Google Scholar
• AFQ056 for language learning in children with FXS. ClinicalTrials.gov. Bethesda, MA: U.S. National Institutes of Health. [ cited 2016 Oct 21]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02920892
   Google Scholar
• Berg D, Godau J, Trenkwalder C, et al. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord. 2011 Jun;26(7):1243–1250.
   PubMed Web of Science ®Google Scholar
• Stocchi F, Rascol O, Destee A, et al. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-Week, randomized, dose-finding study. Mov Disord. 2013 Nov;28(13):1838–1846.
   PubMed Web of Science ®Google Scholar
• Kumar R, Hauser RA, Mostillo J, et al. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson’s disease patients. Int J Neurosci. 2016;126(1):20–24.
   PubMed Web of Science ®Google Scholar
• Stocchi F, Balaguer E, Trenkwalder C, et al. 12-week, double-blind, placebo-controlled, fixed-dose study of immediate release AFQ056, an mGluR5 receptor antagonist, in Parkinson’s disease patients with moderate-to-severe L-dopa induced dyskinesias [abstract]. Move Disord. 2014;29 Suppl 1:723.
   Web of Science ®Google Scholar
• Trenkwalder C, Kulisevsky J, Poewe W, et al. 13-week, double-blind, placebo-controlled, fixed-dose study of modified release AFQ056, an mGluR5 receptor antagonist, in Parkinson’s disease patients with moderate-to-severe L-dopa induced dyskinesias [abstract]. Move Disord. 2014;29 Suppl 1:733.
   Web of Science ®Google Scholar
• Petrov D, Pedros I, De Lemos ML, et al. Mavoglurant as a treatment for Parkinson’s disease. Expert Opin Investig Drugs. 2014;23:1165–1179.
   PubMed Web of Science ®Google Scholar
• Tison F, Keywood C, Wakefield M, et al. A phase 2A trial of the novel mGluR5-negative allosteric modulator dipraglurant for levodopa-induced dyskinesia in Parkinson’s disease. Mov Disord. 2016;31:1373–1380.
   PubMed Web of Science ®Google Scholar
• Addex Therapeutics press release: addex’ dipraglurant receives orphan drug designation from the FDA for levodopa-induced dyskinesia associated with Parkinson’s disease. Geneva (Switzerland). 2016 Jan 4.
   Google Scholar
• Wong DF, Waterhouse R, Kuwabara H, et al. 18F-FPEB, a PET radiopharmaceutical for quantifying metabotropic glutamate 5 receptors: a first-in-human study of radiochemical safety, biokinetics, and radiation dosimetry. J Nucl Med. 2013 Mar;54(3):388–396.
   PubMed Web of Science ®Google Scholar
• Addex Therapeutics press release: addex reports positive results of an mGlu5 receptor occupancy study with dipraglurant in healthy volunteers. Geneva (Switzerland). 2016 Apr 11.
   Google Scholar
• Fuxe K, Borroto-Escuela DO. Basimglurant for treatment of major depressive disorder: a novel negative allosteric modulator of metabotropic glutamate receptor 5. Expert Opin Investig Drugs. 2015;24:1247–1260.
   PubMed Web of Science ®Google Scholar
• Quiroz JA, Tamburri P, Deptula D, et al. Efficacy and safety of basimglurant as adjunctive therapy for major depression: a randomized clinical trial. JAMA Psychiatry. 2016;73:675–684.
   PubMed Web of Science ®Google Scholar
• Pharma Pipeline F Hoffman-La Roche, Ltd. Basel (Switzerland): Roche Product Development Portfolio. [ Updated 2016 Oct 20; cited 2016 Oct 24]. Available from: http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
   Google Scholar
• Novartis AG. Modified release formulation. WO2014199316. 2014.
   Google Scholar
• Addex Pharma SA. Extended release formulations. WO2013186311. 2013.
   Google Scholar
• Addex Pharma SA. Pharmaceutical combination products for Parkinson’s disease. WO2013139941. 2013.
   Google Scholar
• Addex Pharma SA. Mono-phosphate salt of 6-fluoro-2-[4-(pyridin-2-yl)but-3-yn-1-yl]imidazo[1,2a]pyridine and polymorphs thereof as negative allosteric modulator of mGlu5 receptor. WO 2015044270. 2015.
   Google Scholar
• F Hoffman Laroche AG. Ethynyl derivatives as modulators of mGluR5 receptor activity. WO 2014060384. 2014.
   Google Scholar
• F Hoffman LaRoche AG. Ethynyl derivatives as modulators of mGluR5 receptor activity. WO 2014060394. 2014.
   Google Scholar
• F Hoffman LaRoche AG. Ethynyl derivatives as modulators of mGluR5 receptor activity. WO 2014060398. 2014.
   Google Scholar
• Wood MR, Hopkins CR, Brogan JT, et al. “Molecular switches” on mGluR allosteric ligands that modulate modes of pharmacology. Biochem. 2011;50:2403–2410.
   PubMed Web of Science ®Google Scholar
• F Hoffman Laroche AG. Ethynyl derivatives as metabotropic glutamate receptor antagonists. WO 2015004007. 2015.
   Google Scholar
• Merz Pharma GmbH & Co KGaA. Heterocyclic derivatives as metabotropic glutamate receptor modulators. EP2650284. 2013.
   Google Scholar
• Merz Pharma GmbH & Co KGaA. Metabotropic glutamate receptor modulators. WO2012052451. 2012.
   Google Scholar
• H Lundbeck A/S. Bicarboxylic and tricarboxylic ethynyl derivatives and uses of same. WO 2013040535. 2013.
   Google Scholar
• H Lundbeck A/S. Bicyclo[3.2.1]octyl amide derivatives and uses of same. WO 2012088365. 2012.
   Google Scholar
• H Lundbeck A/S. Adamantyl amide derivatives and uses of same. WO 20110087758. 2011.
   Google Scholar
• H Lundbeck A/S. Adamantyl amide derivatives and uses of same. WO 2010011570. 2010.
   Google Scholar
• O’Brien JA, Lemaire W, Chen T-B, et al. A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Mol Pharmacol. 2003;64:731–740.
   PubMed Web of Science ®Google Scholar
• Hua Medicine (Shanghai) Ltd. mGluR regulators. WO 2014124560. 2014.
   Google Scholar
• Korea Institute of Science and Technology. 2-(Substituted ethynyl)quinoline derivatives as mGluR5 antagonists. US20140206876. 2014.
   Google Scholar
• Kim SH, Na HS, Sheen K, et al. Effects of sympathectomy on a rat model of peripheral neuropathy. Pain. 1993;55:85–92.
   PubMed Web of Science ®Google Scholar
• Toray Industries, Inc. Imidazo[1,2-a]pyridine derivatives and use thereof for medical purposes. WO 2013081094. 2013.
   Google Scholar
• Carcache D, Vranesic I, Blanz J, et al. Benzimidazoles as potent and orally active mGlu5 receptor antagonists with an improved PK profile. ACS Med Chem Lett. 2011;2:58–62.
   PubMed Web of Science ®Google Scholar
• Toray Industries, Inc. N-Alkylamide derivative and medicinal use thereof. WO 2015098991. 2015.
   Google Scholar
• Satow A, Maehara S, Ise S, et al. Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC, [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide]. J Pharmacol Exp Ther. 2008;326:577–586.
   PubMed Web of Science ®Google Scholar
• Togashi Y, Umeuchi H, Okano K, et al. Antipruritic activity of the κ-opioid receptor agonist, TRK-820. Eur J Pharmacol. 2002;435:259–264.
   PubMed Web of Science ®Google Scholar
• Montana MC, Gereau RW IV. Metabotropic glutamate receptors as targets for analgesia: antagonism, activation, and allosteric modulation. Curr Pharm Biotechnol. 2011;12:1681–1688.
   PubMed Web of Science ®Google Scholar
• Dainippon Sumitomo Pharma Co Ltd. Tetrahydrooxazolopyridine derivative. JP 2014185092 (2014)
   Google Scholar
• Burdi DF, Hunt R, Fan L, et al. Design, synthesis, and structure−activity relationships of novel bicyclic azole-amines as negative allosteric modulators of metabotropic glutamate receptor 5. J Med Chem. 2010;53:7107–7118.
   PubMed Web of Science ®Google Scholar
• Dainippon Sumitomo Pharma Co., Ltd. Completes Acquisition of Sepracor Inc. Dainippon Sumitomo Pharma Co., Ltd. Osaka (Japan): News Releases. [ cited 2016 Oct 31]. Available from: http://www.ds-pharma.com/news/192009/20091021.html
   Google Scholar
• Youdim MBH, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci. 2006;7:295–309.
   PubMed Web of Science ®Google Scholar
• Dainippon Sumitomo Pharma Co Ltd. Tetrahydrooxazolo-pyridine derivative. WO 2014065270. 2014.
   Google Scholar
• Dainippon Sumitomo Pharma Co Ltd. Tetrahydopyrazolopyrazine derivatives. JP 2015059118. 2015.
   Google Scholar
• Nippon Shinyaku Co Ltd. Pyridine derivative and medicine. WO 2014034898. 2014.
   Google Scholar
• Hunskaar S, Hole K. The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. Pain. 1987;30:103–114.
   PubMed Web of Science ®Google Scholar
• Oyama T, Homan T, Kyotani J, et al. Effect of tramadol on pain-related behaviors and bladder overactivity in rodent cystitis models. Eur J Pharmacol. 2012;676:75–80.
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim International GMBH. Novel pyrazolopyrimidines. WO 2013144172. 2013.
   Google Scholar
• Novo Nordisk A/S. New pyrazolo[1,5-a]pyrimidines derivatives and pharmaceutical uses thereof. WO 2004089471. 2004.
   Google Scholar
• Merz Pharma GMBH & Co KGAA. Enteric formulations of metabotropic glutamate receptor modulators. WO 2012139876. 2012.
   Google Scholar
• Merz Pharma GMBH & Co KGAA. Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine. WO 2008015269. 2008.
   Google Scholar
• Novartis AG Diazepinone derivatives useful for the treatment of fragile X syndrome, Parkinson’s or reflux disease. WO 2014030128. 2014.
   Google Scholar
• Heptares Therapeutics Ltd. 4-(3-Cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators. WO 2015008073. 2015.
   Google Scholar
• Gasparini F, Andres H, Flor PJ, et al. [3H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5. Bioorg Med Chem Lett. 2002;12:407–409.
   PubMed Web of Science ®Google Scholar
• Deacon RMJ. Digging and marble burying in mice: simple methods for in vivo identification of biological impacts. Nat Protocols. 2006;1:122–124.
   PubMed Web of Science ®Google Scholar
• Vanderbilt University. Substituted 4-alkoxypicolinamide analogs as mGluR5 negative allosteric modulators. WO 2015200682. 2015.
   Google Scholar
• Vanderbilt University. Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mGluR5. WO 2015077246. 2015.
   Google Scholar
• Vanderbilt University. Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5. US 20160096833. 2016.
   Google Scholar
• Vanderbilt University. Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators. US 20150266866. 2015.
   Google Scholar
• Vanderbilt University. 6-Alkyl-N-(pyridin-2-yl)-4-aryloxypicolinamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same. WO 2012118563. 2012.
   Google Scholar
• Swedberg MDB, Raboisson P. AZD9272 and AZD2066: selective and highly central nervous system penetrant mGluR5 antagonists characterized by their discriminative effects. J Pharmacol Exp Ther. 2014;350:212–222.
   PubMed Web of Science ®Google Scholar
• Homayoun H, Stefani MR, Adams BW, et al. Functional interaction between NMDA and mGlu5 receptors: effects on working memory, instrumental learning, motor behaviors, and dopamine release. Neuropsychopharmacology. 2004;29:1259–1269.
   PubMed Web of Science ®Google Scholar
• Kinney GG, Burno M, Campbell UC, et al. Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J Pharmacol Exp Ther. 2003;306:116–123.
   PubMed Web of Science ®Google Scholar
• Porter RH, Jaeschke G, Spooren W, et al. Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J Pharmacol Exp Ther. 2005;315:711–721.
   PubMed Web of Science ®Google Scholar
• Nickols HH, Yuh JP, Gregory KJ, et al. VU0477573: partial negative allosteric modulator of the subtype 5 metabotropic glutamate receptor with in vivo efficacy. J Pharmacol Exp Ther. 2016;356:123–136.
   PubMed Web of Science ®Google Scholar
• Gould RW, Amato RJ, Bubser M, et al. Partial mGlu5 negative allosteric modulators attenuate cocaine-mediated behaviors and lack psychotomimetic-like effects. Neuropsychopharmacology. 2016;41:1166–1178.
   PubMed Web of Science ®Google Scholar
• Palanisamy GS, Marcek JM, Cappon GD, et al. Drug-induced skin lesions in cynomolgus macaques treated with metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulators. Toxicol Pathol. 2015;43(7):995–1003.
   PubMed Web of Science ®Google Scholar
• Morin N, Morissette M, Grégoire L, et al. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys. Neuropharmacology. 2013;73:216–231.
   PubMed Web of Science ®Google Scholar
• Masilamoni GJ, Bogenpohl JW, Alagille D, et al. Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys. Brain. 2011;134:2057–2073.
   PubMed Web of Science ®Google Scholar